date,title,source
Oct-17-18,EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq,Zacks
Oct-18-18,EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting,GlobeNewswire
Oct-29-18,EyePoint Pharmaceuticals Presents Positive YUTIQ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting,GlobeNewswire
Oct-30-18,EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information,GlobeNewswire
Oct-30-18,"EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors",GlobeNewswire
Nov-05-18,EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region,GlobeNewswire
